CENTESSA PHARMACEUTICA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

26 Sep 2024 06:00:31 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

12 Sep 2024 22:34:37 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

11 Sep 2024 16:04:47 By Nasdaq GlobeNewswire

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

21 Aug 2024 08:00:45 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

13 Aug 2024 07:00:41 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

10 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

21 May 2024 08:45:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

13 May 2024 16:10:29 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23 Apr 2024 21:36:40 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

23 Apr 2024 16:17:37 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

28 Mar 2024 16:28:47 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

22 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

09 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

22 Jan 2024 08:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

13 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

10 Dec 2023 12:05:00 By Nasdaq GlobeNewswire